Medical Oncology Vol. II
Three topics, 43 cases — choose one below to browse its cases.
FLT3, IDH1, and KMT2A-targeted AML therapy at the edge of trial-enrolled populations, blast-phase CML and double-refractory CLL sequencing after prior targeted-therapy failure, MRD-threshold and post-transplant maintenance decisions in B-ALL and Hodgkin lymphoma, transplant-ineligible myeloma regimen intensity, relapsed lymphoma therapy selection, and germline predisposition and therapy-related myeloid neoplasm risk
Germ cell tumor and prostate cancer regimen and sequencing decisions across trial-enrolled populations, renal cell carcinoma treatment under thin or maturing evidence, and urothelial carcinoma eligibility and sequencing questions in the field's fastest-moving disease area
Driver-mutation-targeted NSCLC therapy (ALK, ROS1, MET, RET, HER2) at the edge of trial-enrolled populations, consolidation and rechallenge decisions after immunotherapy toxicity, small cell lung cancer sequencing under evidence-recency pressure, and mesothelioma and thymoma pharmacology